The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
Toscan CE, McCalmont H, Ashoorzadeh A, Lin X, Fu Z, Doculara L, Kosasih HJ, Cadiz R, Zhou A, Williams S, Evans K, Khalili F, Cai R, Yeats KL, Gifford AJ, Pickford R, Mayoh C, Xie J, Henderson MJ, Trahair TN, Patterson AV, Smaill JB, de Bock CE, Lock RB.
Toscan CE, et al. Among authors: lin x.
Blood Cancer J. 2024 Nov 6;14(1):192. doi: 10.1038/s41408-024-01180-x.
Blood Cancer J. 2024.
PMID: 39505850